NOBIVAC CANINE 1-DAPPV+L4 9-WAY VACCINE

NOBIVAC® CANINE 1-DAPPV+L4

9-WAY VACCINE     25 x 1 mL dose

Description

Recommended for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, adenovirus type 1 (hepatitis), canine parainfluenza virus, and canine parvovirus. Additionally, it is an aid in the prevention of disease, urinary shedding and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa.

9 WAY VACCINE: Canine Distemper, Adenovirus Type 2, Parainfluenza, Parvovirus Vaccine, MODIFIED LIVE VIRUS, Leptospira Canicola- Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin
A multi-purpose 1-year vaccine that has 2 critical indications in the protection against leptospirosis and also protects against all strains of canine parvovirus (CPV).
Features and Benefits
  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c1-2
    • Contains CPV-2b, one of the most prevalent field strains of parvovirus
    • High antigenic mass (titer), low passage
    • Overrides maternal antibodies in young puppies.3
  • The only leptospirosis vaccine to protect and defend against mortality and urinary shedding
  • Prevented mortality caused by 4 virulent Leptospira serovars.3
  • Protects against adenovirus type 1 that causes hepatitis in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, adenovirus type 1 (hepatitis), parainfluenza and parvovirus, in 1 formula
Indications
  • Approved for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, adenovirus type 1, parainfluenza, and parvovirus
  • Indicated as an aid in the prevention of disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa
  • Prevents leptospiruria associated with L. grippotyphosa, L. canicola, or L. icterohaemorrhagiae
  • Aids in the prevention of leptospiruria associated with L. pomona
  • Recommended for use in healthy dogs 8 weeks of age or older
Safety Information
  • Safety confirmed in 749-dog field study3
  • Proven safe across a variety of dog breeds and ages
  • Now featuring an even higher level of quality due to new VacciPure™ filtration
 Please see the product label for safety information.
Administration and Dosage
  • Subcutaneous injection
  • Two 1 mL doses given 2 to 4 weeks apart
  • Repeat at 2 to 4 week intervals until the dog is 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1 mL dose